- Hepatitis Delta Virus (HDV) infection, a severe co-infection with Hepatitis B, poses a significant public health concern due to its aggressive progression to liver cirrhosis and hepatocellular carcinoma, thereby driving increasing demand for early detection, effective therapeutics, and public health intervention strategies across Europe
- The market growth is primarily fueled by rising awareness, improved diagnostic capabilities, and an increasing number of HDV-targeted research initiatives across leading European nations with robust healthcare systems.
- Germany dominated the Europe hepatitis delta virus (HDV) infection market with the largest revenue share of 29.9% in 2024, supported by its comprehensive hepatitis screening programs, government-backed disease elimination plans, and presence of key pharmaceutical players focused on liver diseases
- Italy is expected to be the fastest-growing country in the Europe hepatitis delta virus (HDV) infection market during the forecast period due to its historically higher HDV prevalence, improved patient outreach programs, and increasing healthcare investments in managing chronic liver diseases
- Chronic Hepatitis D segment dominated the Europe hepatitis delta virus (HDV) infection market with a market share of 73% in 2024, driven by its long-term disease burden requiring continuous treatment, monitoring, and higher healthcare resource utilization
